- Home
- LANV vs LUCD Comparison
LANV vs LUCD Comparison
Compare LANV & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LANV | LUCD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | 2066 | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 182.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LANV | LUCD |
|---|---|---|
| Price | $1.46 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 2.8K | ★ 931.4K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | $3.33 | $130.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $1.03 | $0.90 |
| 52 Week High | $2.62 | $1.63 |
Technical Indicators
Market Signals| Indicator | LANV | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 44.48 |
| Support Level | $1.38 | $1.02 |
| Resistance Level | $1.83 | $1.12 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.95 | 54.55 |
Price Performance
Historical ComparisonAbout LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the St. John segment.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.